However, it is also important to note that more than half (54.5%) of MMR pathogenic variant carriers did not report any prior cancer, indicating that history of prior LS‐associated cancer alone has poor sensitivity to delineate patients with EC due to a germline MMR gene defect. The gene discussed is MRC1; the disease is cancer.